Skip to main content

Illumina Q3 FY2026 results

  • ILMN · Nasdaq
  • Instruments
  • Life Sciences Tools & Services
  • S&P 500
$198.26−4.22%Close 16 Nov 2026 · Market value $30.43B

Illumina reported revenue of $1.13 billion, up 4.2% from a year earlier, net income of $220 million and diluted earnings per share of $1.43 against $0.98 for the third quarter of fiscal 2026 (the three months to 27 Sep 2026).

From its quarterly report, the results first announced on 29 Oct 2026. Compiled and checked by AapWire.

Q3 FY2026 against Q3 FY2025

Three months to 27 Sep 2026, against the three months to 28 Sep 2025. Amounts in USD.

Illumina Q3 FY2026 results against the year-ago quarter
MeasureQ3 FY2026Q3 FY2025Change
Revenue$1.13B$1.08B+4.2%
Gross profit$830.0M$733.0M+13.2%
Gross margin73.5%67.6%+5.9 pts
Operating income$305.0M$227.0M+34.4%
Operating margin27.0%20.9%+6.1 pts
Net income$220.0M$150.0M+46.7%
Diluted EPS$1.43$0.98+45.9%
Operating cash flow$419.0M$284.0M+47.5%
Capital expenditure$40.00M$31.00M+29.0%
Free cash flow$379.0M$253.0M+49.8%

Operating KPIs for the quarter

Illumina operating KPIs, Q3 FY2026
KPIQ3 FY2026Change on a year
Consumables revenue$841.0Mup 3.1%
Service revenue$183.0Mup 16.6%
Instruments revenue$105.0Mdown 5.4%
Core Illumina revenue$1.1Bup 4.2%
Sequencing revenue$1.0Bup 2.0%
Microarray revenue$108.0Mup 30.1%
China revenue$59.0Mup 13.5%

Earlier quarters

Illumina results, last eight filed quarters
QuarterPeriod endRevenueChange on a yearDiluted EPS
Q3 FY202627 Sep 2026$1.13B+4.2%$1.43
Q2 FY202628 Jun 2026$1.16B+9.4%$1.35
Q1 FY202629 Mar 2026$1.09B+4.8%$0.87
Q4 FY202528 Dec 2025$1.16B+5.0%$2.18
Q3 FY202528 Sep 2025$1.08B+0.4%$0.98
Q2 FY202529 Jun 2025$1.06B−4.8%$1.49
Q1 FY202530 Mar 2025$1.04B−3.3%$0.82
Q4 FY202429 Dec 2024$1.10B−1.6%$1.17

More on Illumina: financial statements · revenue · earnings per share

ILMN's results, as they are filed.

Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.